Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 1/2020

21.12.2019 | Research Article

The inappropriate use of proton pump inhibitors during admission and after discharge: a prospective cross-sectional study

verfasst von: Onuma Sattayalertyanyong, Premrutai Thitilertdecha, Chonticha Auesomwang

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Background Proton pump inhibitors are often inappropriately prescribed during hospital admission and after discharge. The inappropriate prescription may be associated with increased and unnecessary healthcare costs. Objective To determine the prevalence of inappropriate prescription of proton pump inhibitors during hospital admission and after discharge at Thailand’s largest national tertiary referral center. Setting Medicine wards at Siriraj Hospital (Bangkok, Thailand) during September 2016 to September 2017. Method This prospective observational cross-sectional study in hospitalized patients who were prescribed, or who were already taking proton pump inhibitors. Medical records were reviewed to determine whether proton pump inhibitors were prescribed at discharge and at the 1-month follow-up. Main outcome measure Prevalence of inappropriate prescription of proton pump inhibitors during hospital admission and after discharge, indication of inappropriate prescription. Results Two hundred and sixty-five patients (mean age: 65.8 ± 18.3 years, 50.9% men) were included. Approximately half of patients had proton pump inhibitor treatment initiated in the hospital, and the other 50.6% started treatment earlier. Among all patients, 50.6% were inappropriately prescribed proton pump inhibitors, in which 79.1% resulted from invalid indications. Fifty-two percent and 47.3% of patients who were prescribed proton pump inhibitors at discharge and at the 1-month follow-up had no indications for them. Gastrointestinal ulcer prophylaxis in low-risk patients was the most commonly observed incorrect indication. Aspirin (p = 0.030) and corticosteroids (p = 0.038) were both found to be significantly associated with the inappropriate prescription of proton pump inhibitors. The estimated cost of inappropriate use among inpatients and outpatients was $118,659 and $214,663 per year, respectively. Conclusion Proton pump inhibitors are excessively and inappropriately prescribed during hospital admission and after discharge in Thailand. The cost of this overprescribing is excessive and needs to be controlled.
Literatur
1.
Zurück zum Zitat Ford AC, Moayyedi P. Current guidelines for dyspepsia management. Dig Dis. 2008;26(3):225–30.PubMed Ford AC, Moayyedi P. Current guidelines for dyspepsia management. Dig Dis. 2008;26(3):225–30.PubMed
2.
Zurück zum Zitat Talley NJ, Vakil N. Practice parameters committee of the American College of G. Guidelines for the management of dyspepsia. Am J Gastroenterol. 2005;100(10):2324–37.PubMed Talley NJ, Vakil N. Practice parameters committee of the American College of G. Guidelines for the management of dyspepsia. Am J Gastroenterol. 2005;100(10):2324–37.PubMed
3.
Zurück zum Zitat Lanza FL, Chan FK, Quigley EM. Practice parameters committee of the American College of G. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3):728–38.PubMed Lanza FL, Chan FK, Quigley EM. Practice parameters committee of the American College of G. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3):728–38.PubMed
4.
Zurück zum Zitat Niaz SK, Quraishy MS, Taj MA, Abid S, Alam A, Nawaz AA, et al. Guidelines on gastroesophageal reflux disease. J Pak Med Assoc. 2015;65(5):532–41.PubMed Niaz SK, Quraishy MS, Taj MA, Abid S, Alam A, Nawaz AA, et al. Guidelines on gastroesophageal reflux disease. J Pak Med Assoc. 2015;65(5):532–41.PubMed
5.
Zurück zum Zitat Mohebbi L, Hesch K. Stress ulcer prophylaxis in the intensive care unit. Bayl Univ Med Cent Proc. 2009;22(4):373–6. Mohebbi L, Hesch K. Stress ulcer prophylaxis in the intensive care unit. Bayl Univ Med Cent Proc. 2009;22(4):373–6.
6.
Zurück zum Zitat Morneau KM, Reaves AB, Martin JB, Oliphant CS. Analysis of gastrointestinal prophylaxis in patients receiving dual antiplatelet therapy with aspirin and clopidogrel. J Manag Care Pharm. 2014;20(2):187–93.PubMed Morneau KM, Reaves AB, Martin JB, Oliphant CS. Analysis of gastrointestinal prophylaxis in patients receiving dual antiplatelet therapy with aspirin and clopidogrel. J Manag Care Pharm. 2014;20(2):187–93.PubMed
7.
Zurück zum Zitat Villamanan E, Ruano M, Lara C, Suarez-de-Parga JM, Armada E, Alvarez-Sala R, et al. Reasons for initiation of proton pump inhibitor therapy for hospitalised patients and its impact on outpatient prescription in primary care. Rev Esp Enferm Dig. 2015;107(11):652–8.PubMed Villamanan E, Ruano M, Lara C, Suarez-de-Parga JM, Armada E, Alvarez-Sala R, et al. Reasons for initiation of proton pump inhibitor therapy for hospitalised patients and its impact on outpatient prescription in primary care. Rev Esp Enferm Dig. 2015;107(11):652–8.PubMed
8.
Zurück zum Zitat Ahrens D, Behrens G, Himmel W, Kochen MM, Chenot JF. Appropriateness of proton pump inhibitor recommendations at hospital discharge and continuation in primary care. Int J Clin Pract. 2012;66(8):767–73.PubMed Ahrens D, Behrens G, Himmel W, Kochen MM, Chenot JF. Appropriateness of proton pump inhibitor recommendations at hospital discharge and continuation in primary care. Int J Clin Pract. 2012;66(8):767–73.PubMed
9.
Zurück zum Zitat Ahrens D, Chenot JF, Behrens G, Grimmsmann T, Kochen MM. Appropriateness of treatment recommendations for PPI in hospital discharge letters. Eur J Clin Pharmacol. 2010;66(12):1265–71.PubMedPubMedCentral Ahrens D, Chenot JF, Behrens G, Grimmsmann T, Kochen MM. Appropriateness of treatment recommendations for PPI in hospital discharge letters. Eur J Clin Pharmacol. 2010;66(12):1265–71.PubMedPubMedCentral
10.
Zurück zum Zitat Akram F, Huang Y, Lim V, Huggan PJ, Merchant RA. Proton pump inhibitors: are we still prescribing them without valid indications? Australas Med J. 2014;7(11):465–70.PubMedPubMedCentral Akram F, Huang Y, Lim V, Huggan PJ, Merchant RA. Proton pump inhibitors: are we still prescribing them without valid indications? Australas Med J. 2014;7(11):465–70.PubMedPubMedCentral
11.
Zurück zum Zitat Haroon M, Yasin F, Gardezi SK, Adeeb F, Walker F. Inappropriate use of proton pump inhibitors among medical inpatients: a questionnaire-based observational study. JRSM Short Rep. 2013;4(8):1–6. Haroon M, Yasin F, Gardezi SK, Adeeb F, Walker F. Inappropriate use of proton pump inhibitors among medical inpatients: a questionnaire-based observational study. JRSM Short Rep. 2013;4(8):1–6.
12.
Zurück zum Zitat Perwaiz MK, Posner G, Hammoudeh F, Schmidt F, Neupane N, Enriquez D, et al. Inappropriate use of intravenous PPI for stress ulcer prophylaxis in an inner city community hospital. J Clin Med Res. 2010;2(5):215–9.PubMedPubMedCentral Perwaiz MK, Posner G, Hammoudeh F, Schmidt F, Neupane N, Enriquez D, et al. Inappropriate use of intravenous PPI for stress ulcer prophylaxis in an inner city community hospital. J Clin Med Res. 2010;2(5):215–9.PubMedPubMedCentral
13.
Zurück zum Zitat Shin S. Evaluation of costs accrued through inadvertent continuation of hospital-initiated proton pump inhibitor therapy for stress ulcer prophylaxis beyond hospital discharge: a retrospective chart review. Ther Clin Risk Manag. 2015;11:649–57.PubMedPubMedCentral Shin S. Evaluation of costs accrued through inadvertent continuation of hospital-initiated proton pump inhibitor therapy for stress ulcer prophylaxis beyond hospital discharge: a retrospective chart review. Ther Clin Risk Manag. 2015;11:649–57.PubMedPubMedCentral
14.
Zurück zum Zitat Eid SM, Boueiz A, Paranji S, Mativo C, Landis R, Abougergi MS. Patterns and predictors of proton pump inhibitor overuse among academic and non-academic hospitalists. Intern Med. 2010;49(23):2561–8.PubMed Eid SM, Boueiz A, Paranji S, Mativo C, Landis R, Abougergi MS. Patterns and predictors of proton pump inhibitor overuse among academic and non-academic hospitalists. Intern Med. 2010;49(23):2561–8.PubMed
15.
Zurück zum Zitat Martin-Echevarria E, Pereira Julia A, Torralba M, Arriola Pereda G, Martin Davila P, Mateos J, et al. Assessing the use of proton pump inhibitors in an internal medicine department. Rev Esp Enferm Dig. 2008;100(2):76–81.PubMed Martin-Echevarria E, Pereira Julia A, Torralba M, Arriola Pereda G, Martin Davila P, Mateos J, et al. Assessing the use of proton pump inhibitors in an internal medicine department. Rev Esp Enferm Dig. 2008;100(2):76–81.PubMed
16.
Zurück zum Zitat Reid M, Keniston A, Heller JC, Miller M, Medvedev S, Albert RK. Inappropriate prescribing of proton pump inhibitors in hospitalized patients. J Hosp Med. 2012;7(5):421–5.PubMed Reid M, Keniston A, Heller JC, Miller M, Medvedev S, Albert RK. Inappropriate prescribing of proton pump inhibitors in hospitalized patients. J Hosp Med. 2012;7(5):421–5.PubMed
17.
Zurück zum Zitat Sirivunnabood S, Barameerungsikul C. Proton pump inhibitors for stress ulcer prophylaxis in general wards. R Thai Air Force Med Gaz. 2011;57(2):1–5. Sirivunnabood S, Barameerungsikul C. Proton pump inhibitors for stress ulcer prophylaxis in general wards. R Thai Air Force Med Gaz. 2011;57(2):1–5.
18.
Zurück zum Zitat Savarino V, Dulbecco P, de Bortoli N, Ottonello A, Savarino E. The appropriate use of proton pump inhibitors (PPIs): need for a reappraisal. Eur J Intern Med. 2017;37:19–24.PubMed Savarino V, Dulbecco P, de Bortoli N, Ottonello A, Savarino E. The appropriate use of proton pump inhibitors (PPIs): need for a reappraisal. Eur J Intern Med. 2017;37:19–24.PubMed
19.
Zurück zum Zitat Parente F, Cucino C, Gallus S, Bargiggia S, Greco S, Pastore L, et al. Hospital use of acid-suppressive medications and its fall-out on prescribing in general practice: a 1-month survey. Aliment Pharmacol Ther. 2003;17(12):1503–6.PubMed Parente F, Cucino C, Gallus S, Bargiggia S, Greco S, Pastore L, et al. Hospital use of acid-suppressive medications and its fall-out on prescribing in general practice: a 1-month survey. Aliment Pharmacol Ther. 2003;17(12):1503–6.PubMed
20.
Zurück zum Zitat Zink DA, Pohlman M, Barnes M, Cannon ME. Long-term use of acid suppression started inappropriately during hospitalization. Aliment Pharmacol Ther. 2005;21(10):1203–9.PubMed Zink DA, Pohlman M, Barnes M, Cannon ME. Long-term use of acid suppression started inappropriately during hospitalization. Aliment Pharmacol Ther. 2005;21(10):1203–9.PubMed
21.
Zurück zum Zitat Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA. 2009;301(20):2120–8.PubMed Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA. 2009;301(20):2120–8.PubMed
22.
Zurück zum Zitat Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk in PPI. Am J Gastroenterol. 2009;104(Suppl 2):S27–32.PubMed Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk in PPI. Am J Gastroenterol. 2009;104(Suppl 2):S27–32.PubMed
23.
Zurück zum Zitat Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292(16):1955–60.PubMed Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292(16):1955–60.PubMed
24.
Zurück zum Zitat Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010;170(9):784–90.PubMed Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010;170(9):784–90.PubMed
25.
Zurück zum Zitat Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005;294(23):2989–95.PubMed Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005;294(23):2989–95.PubMed
26.
Zurück zum Zitat Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011;106(7):1209–18 (quiz 19).PubMed Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011;106(7):1209–18 (quiz 19).PubMed
27.
Zurück zum Zitat Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006;79(2):76–83.PubMed Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006;79(2):76–83.PubMed
28.
Zurück zum Zitat Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947–53.PubMed Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947–53.PubMed
29.
Zurück zum Zitat Heidelbaugh JJ. Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications. Ther Adv Drug Saf. 2013;4(3):125–33.PubMedPubMedCentral Heidelbaugh JJ. Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications. Ther Adv Drug Saf. 2013;4(3):125–33.PubMedPubMedCentral
30.
Zurück zum Zitat Ladd AM, Panagopoulos G, Cohen J, Mar N, Graham R. Potential costs of inappropriate use of proton pump inhibitors. Am J Med Sci. 2014;347(6):446–51.PubMed Ladd AM, Panagopoulos G, Cohen J, Mar N, Graham R. Potential costs of inappropriate use of proton pump inhibitors. Am J Med Sci. 2014;347(6):446–51.PubMed
31.
Zurück zum Zitat Freston JW. Review article: role of proton pump inhibitors in non-H pylori-related ulcers. Aliment Pharmacol Ther. 2001;15(Suppl 2):2–5.PubMed Freston JW. Review article: role of proton pump inhibitors in non-H pylori-related ulcers. Aliment Pharmacol Ther. 2001;15(Suppl 2):2–5.PubMed
32.
Zurück zum Zitat Wilcox CM, Hirschowitz BI. Treatment strategies for Zollinger-Ellison syndrome. Expert Opin Pharmacother. 2009;10(7):1145–57.PubMed Wilcox CM, Hirschowitz BI. Treatment strategies for Zollinger-Ellison syndrome. Expert Opin Pharmacother. 2009;10(7):1145–57.PubMed
33.
Zurück zum Zitat Bhatt DLSJ, Abraham NS, Antman EM, Chan FK, Furberg CD, et al. ACCF/ACG/AHA2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. J Am Coll Cardiol. 2008;52(18):1502.PubMed Bhatt DLSJ, Abraham NS, Antman EM, Chan FK, Furberg CD, et al. ACCF/ACG/AHA2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. J Am Coll Cardiol. 2008;52(18):1502.PubMed
34.
Zurück zum Zitat Zeitoun A, Zeineddine M, Dimassi H. Stress ulcer prophylaxis guidelines: are they being implemented in Lebanese health care centers? World J Gastrointest Pharmacol Ther. 2011;2(4):27–35.PubMedPubMedCentral Zeitoun A, Zeineddine M, Dimassi H. Stress ulcer prophylaxis guidelines: are they being implemented in Lebanese health care centers? World J Gastrointest Pharmacol Ther. 2011;2(4):27–35.PubMedPubMedCentral
35.
36.
Zurück zum Zitat Monnig AA, Prittie JE. A review of stress-related mucosal disease. J Vet Emerg Crit Care (San Antonio). 2011;21(5):484–95. Monnig AA, Prittie JE. A review of stress-related mucosal disease. J Vet Emerg Crit Care (San Antonio). 2011;21(5):484–95.
37.
Zurück zum Zitat Khalili H, Dashti-Khavidaki S, Hossein Talasaz AH, Tabeefar H, Hendoiee N. Descriptive analysis of a clinical pharmacy intervention to improve the appropriate use of stress ulcer prophylaxis in a hospital infectious disease ward. J Manag Care Pharm. 2010;16(2):114–21.PubMed Khalili H, Dashti-Khavidaki S, Hossein Talasaz AH, Tabeefar H, Hendoiee N. Descriptive analysis of a clinical pharmacy intervention to improve the appropriate use of stress ulcer prophylaxis in a hospital infectious disease ward. J Manag Care Pharm. 2010;16(2):114–21.PubMed
38.
Zurück zum Zitat Elena R, Su HL, Alberto MB, Enrique P, Salvador F, Raul M, et al. Overuse of PPIs in patients at admission, during hospitalisation, and at discharge in a tertiary Spanish hospital. Curr Clin Pharmacol. 2010;5(4):288–97. Elena R, Su HL, Alberto MB, Enrique P, Salvador F, Raul M, et al. Overuse of PPIs in patients at admission, during hospitalisation, and at discharge in a tertiary Spanish hospital. Curr Clin Pharmacol. 2010;5(4):288–97.
39.
Zurück zum Zitat van Vliet EPM, Otten HJAM, Rudolphus A, Knoester PD, Hoogsteden HC, Kuipers EJ, et al. Inappropriate prescription of proton pump inhibitors on two pulmonary medicine wards. Eur J Gastroenterol Hepatol. 2008;20(7):608–12.PubMed van Vliet EPM, Otten HJAM, Rudolphus A, Knoester PD, Hoogsteden HC, Kuipers EJ, et al. Inappropriate prescription of proton pump inhibitors on two pulmonary medicine wards. Eur J Gastroenterol Hepatol. 2008;20(7):608–12.PubMed
40.
Zurück zum Zitat Thomas L, Culley EJ, Gladowski P, Goff V, Fong J, Marche SM. Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large managed care organization. J Manag Care Pharm. 2010;16(2):122–9.PubMed Thomas L, Culley EJ, Gladowski P, Goff V, Fong J, Marche SM. Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large managed care organization. J Manag Care Pharm. 2010;16(2):122–9.PubMed
41.
Zurück zum Zitat Batuwitage BT, Kingham JG, Morgan NE, Bartlett RL. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J. 2007;83(975):66–8.PubMedPubMedCentral Batuwitage BT, Kingham JG, Morgan NE, Bartlett RL. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J. 2007;83(975):66–8.PubMedPubMedCentral
42.
Zurück zum Zitat Heidelbaugh JJ, Kim AH, Chang R, Walker PC. Overutilization of proton-pump inhibitors: what the clinician needs to know. Therap Adv Gastroenterol. 2012;5(4):219–32.PubMedPubMedCentral Heidelbaugh JJ, Kim AH, Chang R, Walker PC. Overutilization of proton-pump inhibitors: what the clinician needs to know. Therap Adv Gastroenterol. 2012;5(4):219–32.PubMedPubMedCentral
Metadaten
Titel
The inappropriate use of proton pump inhibitors during admission and after discharge: a prospective cross-sectional study
verfasst von
Onuma Sattayalertyanyong
Premrutai Thitilertdecha
Chonticha Auesomwang
Publikationsdatum
21.12.2019
Verlag
Springer International Publishing
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 1/2020
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-019-00955-8

Weitere Artikel der Ausgabe 1/2020

International Journal of Clinical Pharmacy 1/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.